Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 3/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638764 | 0.92 | PDE4B (0.43) | CTSACASRPDE4BPTPN5ACLY | |
| SCHEMBL1639378 | 0.85 | PTPN5 (0.41) | CTSACASRHTR7PTPRCPTPN1 | |
| SCHEMBL12646977 | 0.85 | PDE4B (0.45) | PDE4BACLY | |
| SCHEMBL12646926 | 0.84 | AKR1C3 (0.44) | AKR1C3AKR1C2 | |
| SCHEMBL1639068 | 0.81 | PTPN5 (0.46) | CTSACASRHTR7PDE4BPTPN5 | |
| SCHEMBL1639130 | 0.80 | PDE4B (0.42) | PDE4BACLY | |
| SCHEMBL13913537 | 0.77 | HDAC4 (0.57) | CTSACASRHTR7PTPRCPTPN1 | |
| SCHEMBL29430223 | 0.76 | CASR (0.50) | CTSACASRHTR7PTPRCPTPN1 | |
| SCHEMBL31689002 | 0.76 | AKR1C3 (0.65) | CTSAAKR1C3AKR1C2 | |
| SCHEMBL3670700 | 0.76 | AKR1C3 (0.65) | CTSAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493932-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | CTSA 3480/4885CASR 4376/4885HTR7 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.